Aurora Cannabis Reports Robust Q3 Earnings Growth

Aurora Cannabis (US) ( (ACB) ) has released its Q3 earnings. Here is a breakdown of the information Aurora Cannabis (US) presented to its investors.

Aurora Cannabis is a Canada-based global medical cannabis company, recognized for its leadership in the cannabis industry and its focus on high-quality products for medical and consumer markets. In the third quarter of fiscal 2025, Aurora Cannabis reported significant financial achievements, including a 37% year-over-year increase in total net revenue, reaching $88.2 million, and a notable 282% rise in net income to $31.2 million. The company also achieved a record adjusted EBITDA of $23.1 million, marking a 316% increase from the previous year. Aurora’s global medical cannabis business was a major growth driver, contributing to a 51% increase in net revenue for this segment, with international sales growing by 112% and accounting for 60% of the global medical cannabis revenue. The company also posted positive free cash flow of $27.4 million and maintained a strong balance sheet with $180 million in cash and a debt-free cannabis business. Looking ahead, Aurora Cannabis aims to continue its strategic growth and operational excellence. The company anticipates further revenue growth across its cannabis business, with expectations for strong margins and sustained positive adjusted EBITDA and free cash flow. Aurora’s management remains committed to long-term profitability and leveraging its robust financial position to lead the global cannabis market.